Lantern Pharma Inc. (LTRN)

Lantern Pharma Statistics

Total Valuation

Lantern Pharma has a market cap or net worth of $35.48 million. The enterprise value is $28.37 million.

Market Cap	35.48M
Enterprise Value	28.37M

Important Dates

The last earnings date was Friday, May 15, 2026, after market close.

Earnings Date	May 15, 2026
Ex-Dividend Date	n/a

Share Statistics

Lantern Pharma has 11.21 million shares outstanding. The number of shares has increased by 2.25% in one year.

Current Share Class	11.21M
Shares Outstanding	11.21M
Shares Change (YoY)	+2.25%
Shares Change (QoQ)	-0.57%
Owned by Insiders (%)	3.26%
Owned by Institutions (%)	11.10%
Float	8.53M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	10.09
P/TBV Ratio	10.05
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 1.87, with a Debt / Equity ratio of 0.02.

Current Ratio	1.87
Quick Ratio	1.67
Debt / Equity	0.02
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -157.37% and return on invested capital (ROIC) is -101.40%.

Return on Equity (ROE)	-157.37%
Return on Assets (ROA)	-73.31%
Return on Invested Capital (ROIC)	-101.40%
Return on Capital Employed (ROCE)	-482.04%
Weighted Average Cost of Capital (WACC)	15.77%
Revenue Per Employee	n/a
Profits Per Employee	-$994,489
Employee Count	16
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -11.30% in the last 52 weeks. The beta is 2.10, so Lantern Pharma's price volatility has been higher than the market average.

Beta (5Y)	2.10
52-Week Price Change	-11.30%
50-Day Moving Average	2.25
200-Day Moving Average	3.31
Relative Strength Index (RSI)	68.63
Average Volume (20 Days)	301,184

Short Selling Information

The latest short interest is 2.02 million, so 17.98% of the outstanding shares have been sold short.

Short Interest	2.02M
Short Previous Month	1.74M
Short % of Shares Out	17.98%
Short % of Float	23.62%
Short Ratio (days to cover)	1.73

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-16.61M
Pretax Income	-15.91M
Net Income	-15.91M
EBITDA	-16.59M
EBIT	-16.61M
Earnings Per Share (EPS)	-$1.45

Balance Sheet

The company has $6.32 million in cash and $59,076 in debt, with a net cash position of $6.26 million or $0.56 per share.

Cash & Cash Equivalents	6.32M
Total Debt	59,076
Net Cash	6.26M
Net Cash Per Share	$0.56
Equity (Book Value)	3.45M
Book Value Per Share	0.31
Working Capital	3.28M

Cash Flow

In the last 12 months, operating cash flow was -$15.07 million and capital expenditures -$556, giving a free cash flow of -$15.07 million.

Operating Cash Flow	-15.07M
Capital Expenditures	-556
Depreciation & Amortization	16,559
Net Borrowing	n/a
Free Cash Flow	-15.07M
FCF Per Share	-$1.34

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Lantern Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-2.25%
Shareholder Yield	-2.25%
Earnings Yield	-45.94%
FCF Yield	-43.52%

Analyst Forecast

The average price target for Lantern Pharma is $20.00, which is 531.91% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$20.00
Price Target Difference	531.91%
Analyst Consensus	Strong Buy
Analyst Count	2
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	9.10%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	1